In vitro activity of tigecycline against pathogens isolated from lower respiratory infections The Global T.E.S.T. Program 2007
Abstract number: R2289
Hackel M., Badal R., Bouchillon S., Johnson J., Hoban D., Johnson B., Dowzicky M.
Objectives: Tigecycline (TIG), a new glycylcycline, has been shown to have potent broad spectrum activity against most commonly encountered species responsible for community and hospital acquired infections. The Tigecycline Evaluation Surveillance Trial (TEST), a global longitudinal surveillance study, determined the in vitro activity of TIG and 13 comparators against Gram-positive and Gram-negative species isolated from lower respiratory infections.
Methods: 6,266 lower respiratory pathogens from 42 countries were analysed in this survey. The isolates were identified to the species level at the participating sites and confirmed by the central laboratory. MICs were determined by each site using supplied broth microdilution panels and interpreted according to CLSI guidelines.
Results: TIG activity against pathogens isolated from lower respiratory infections is shown in the table.
Conclusions: Tigecycline showed excellent inhibitory activity against all pathogens from lower respiratory infections in this study, with the exception of P. aeruginosa. Tigecycline demonstrated MIC90 values of 0.5 mg/ml against Gram-positive pathogens (including resistant phenotypes) and MIC50 values of 1 mg/ml against the Enterobacteriaceae and Acinetobacter spp., validating the potent inhibitory activity of TIG against these pathogens.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|